THE SCALABLE SOLUTION TO STEM CELL EXPANSION

hr-home

Cytomatrix is a Melbourne based stem cell therapeutics company, that offers a scalable solution to bone marrow transplantation utilising 3D expanded allogeneic cord blood

 

Patients diagnosed with leukaemia and other indications require treatments such as bone marrow or cord blood transplants. Cord blood, from the umbilical cord and placenta, contains “Haemopoietic stem cells” (HSCs) which once transferred to the patient produce further blood cells.

“The critical advantages of the new technology are: culture in 3 dimensions, scalability and incorporation of world leading technologies.”

First to market 3D HSC expansion

Cytomatrix will be first to market with commercial 3D HSC expansion.

The most scalable solution

Cytomatrix will be the most scalable solution.

Provides an "off the shelf" approach

Cytomatrix will be the best suited to an “off the shelf” approach.

Leading delta-1 ligand

Will incorporate the leading proven technology.

Faster path to regulatory approval because of existing clinical data

The Board

Mr. Ben Bergo, Chairman
Mr. Iain Ralph
A/Prof. Mark Kirkland, Chief Scientific Officer

Executive Team

Mr. Robert Atwill, CEO
Mr. Darren Scotti, CFO,
Company Secretary

 

Research Team

Biomaterials Research Team (Deakin)
Prof. Peter Hodgson
Prof. Xungai Wang
Dr. Alessandra Sutti
Dr. Marzieh Parhizkar
Graeme Keating
Nishat Sharma

Cell Biology Research Team (Deakin and MIMR-PHI)
Prof. Graham Jenkin
Dr. Cynthia Wong
Dr. Abhilasha Tiwari
Dr. Julie Sharp
Courtney MacDonald
Christina Kirkland
Lakshmi Nekkanti

 

Company Details

Email: info@cytomatrix.com.au

Level 1, 465 Auburn Road
Hawthorn East, Victoria, 3123,
Australia

Contact Form

 

* NAME

* EMAIL ADDRESS

CONTACT PHONE

COMPANY NAME

* YOUR MESSAGE

* REQUIRED FIELD